Physician profile
Hsiangfeng Tsai
NPI 1164806634
$4,573.14
in general payments reported to CMS, 2019-2025
15 companies · $789 in 2025
The $789 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $715 · 2023: $1,377 · 2024: $836 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,115.36 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $605.42 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.05 | 2021-2025 | Caplyta |
| Alkermes, INC. | $578.41 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $329.99 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $254.72 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $247.29 | 2021-2025 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $236.06 | 2023-2024 | Auvelity |
| Abbvie INC. | $172.16 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $169.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $96.39 | 2023 | Spravato |
| Corium, LLC | $73.25 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $45.68 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $37.71 | 2022-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $18.41 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiangfeng Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.